unknown
Stage
2018
Founded
2
Investors
About
Upstream Bio is developing verekitug, a clinical-stage antagonist targeting the TSLP receptor to treat chronic respiratory diseases driven by inflammation, such as severe asthma, CRSwNP, and COPD.
Explore Upstream Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.